These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37038139)

  • 41. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
    Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Copy number variation in plasma as a tool for lung cancer prediction using Extreme Gradient Boosting (XGBoost) classifier.
    Yu D; Liu Z; Su C; Han Y; Duan X; Zhang R; Liu X; Yang Y; Xu S
    Thorac Cancer; 2020 Jan; 11(1):95-102. PubMed ID: 31694073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients.
    Ponomaryova AA; Rykova EY; Cherdyntseva NV; Skvortsova TE; Dobrodeev AY; Zav'yalov AA; Bryzgalov LO; Tuzikov SA; Vlassov VV; Laktionov PP
    Lung Cancer; 2013 Sep; 81(3):397-403. PubMed ID: 23806794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
    Suga Y; Miyajima K; Oikawa T; Maeda J; Usuda J; Kajiwara N; Ohira T; Uchida O; Tsuboi M; Hirano T; Kato H; Ikeda N
    Oncol Rep; 2008 Nov; 20(5):1137-42. PubMed ID: 18949413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection.
    Su Y; Fang H; Jiang F
    Clin Epigenetics; 2016; 8():109. PubMed ID: 27777637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer.
    Wu Y; Du X; Xue C; Li D; Zheng Q; Li X; Chen H
    Med Oncol; 2013 Dec; 30(4):737. PubMed ID: 24126941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
    Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
    Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential circulating miRNA signature for early detection of NSCLC.
    Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
    Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
    Jang H; Choi CM; Lee SH; Lee S; Jeong MK
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Sight of the Diagnostic Value of Aberrant Cell-Free DNA Methylation in Lung Cancer.
    Zhao H; Zhang H; Xu W; Wen B; Kang Y
    Dis Markers; 2022; 2022():9619357. PubMed ID: 35126793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
    Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
    J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients.
    Bach S; Wever BMM; van de Wiel MA; Veltman JD; Hashemi SMS; Kazemier G; Bahce I; Steenbergen RDM
    Epigenetics; 2022 Oct; 17(10):1057-1069. PubMed ID: 34605346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The expression and significance of stem cell transcription factor Sox2 in lung carcinoma].
    Xu W; Wei Y; Tan Y; Xu W; Cheng SY; Wu J
    Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):591-5. PubMed ID: 24229625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer.
    Cao YT; Li JH; Wang YT; Fu YW; Xu J
    Tumori; 2014; 100(2):214-8. PubMed ID: 24852868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.